Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema

Li Huyu; Liu Dongdong; Liu Chao

doi:doi:10.11648/j.cmr.20241302.12

Case Report |

| Peer-Reviewed

Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema

Li Huyu^*

, Liu Dongdong

, Liu Chao

Published in Clinical Medicine Research (Volume 13, Issue 2)

Received: 16 April 2024 Accepted: 13 May 2024 Published: 30 May 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.

Published in	Clinical Medicine Research (Volume 13, Issue 2)
DOI	10.11648/j.cmr.20241302.12
Page(s)	23-28
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

External Human Epidermal Growth Factor, Ebastine, Treatment of Eczema, Skin Inflammation, Environmental Factors

References

[1]	Sun Z G, LU J Z, ZHOU S J, et al. Research progress of traditional Chinese medicine in the treatment of eczema [J]. Chin J Traditional Chinese Medicine, 2022, (8): 3617-3619.
[2]	Soobin Jang, Hyo In Kim, Jae Woo Jung, Mina Boo, Soo-Hyun Sung, Jinbong Park, Sungha Kim. Bee venom acupuncture and herbal medicine for hand eczema: Two case reports and an in vivo studyAffiliations expand PMID: 38637265 Explore (NY). 2024 Mar 21: S1550-8307(24)00057-0. https://doi.org/10.1016/j.explore.2024.03.002
[3]	Zhai Y, Zhang F C, Jiang Y, et al. Clinical experience of treating eczema with traditional Chinese medicine [J]. Chin J Traditional Chinese Medicine, 2023, (6): 2199-2201.
[4]	LI G Q, Chen M C. Effect of UVA-UVB combined with encapsulation on eczema based on quantitative observation of EASI [J]. Guangdong Med, 2016, 37(15): 2327-2331.
[5]	Xue Y, Liu X Y, Gao H B, et al. Study on the mechanism of the treatment of eczema and dermatitis by Longiphylla sinensis [J]. Chinese Materia Medica Pharmacology & Clinic, 2017, 4(3): 120-123.
[6]	Tam H, Calderon M A, Manikam L, etal. Speciﬁc allergen immunotherapy for the treatment of atopic Eczema [J]. Journal of Allergy and 2023 states (9): 1345-1356.
[7]	ZHANG H S. Clinical effect of Longzhu ointment combined with triamcinolone acetonide and econazole cream in the treatment of eczema [J]. Chin J Dermatology, 2023, 49(2): 131-132.
[8]	Lei Q, WANG J G, Huang D Q. Clinical observation of oral and external use of traditional Chinese medicine in the treatment of chronic anal eczema with blood deficiency and wind dryness [J]. China Journal of Basic Medicine of Traditional Chinese Medicine, 2023, 9(3): 428-430.
[9]	Chong M, Fonacier L. T reatment of Eczema: Corticosteroids and Beyond [J]. Journal of Clinical Reviews in Allergy & Immunology, 2023 ploidy (3): 249-262.
[10]	Tarnuzzer RW, Macauley SP, Mast BA, Gibson JS, et al.: Epidermal growth factor in wound healing: a model for the molecular pathogenesis of chronic wounds. In: Ziegler TR, Pierce GF, Herndon DN. (eds): “Growth Factors and Wound Healing”, 206-28, Springer; USA, 1997. [Google Scholar]
[11]	Chen Gang, Cheng Zuyao, Wang Wenda. Effect of recombinant human basic fibroblast growth factor on the treatment of acute exudative infantile eczema [J]. Chinese Rural Medicine, 2022, 26(11): 32-33.
[12]	Liu Huiping, Zhao Shuying, Wei Xia. Efficacy analysis of intense pulsed light combined with recombinant human epidermal growth factor gel in the treatment of facial glucocorticoid-dependent dermatitis [J]. Chinese Medical Cosmetology, 2023, 8(5): 50-54.
[13]	Rohovsky S, D’Amore PA: Growth factors and angiogenesis in wound healing. In: Thomas RZ, Pierce GF, Herndon DN. (eds): “Growth Factors and Wound Healing”, 8-26, Springer, New York, 1997. [Google Scholar]
[14]	Ju WD, Schiller JT, Kazempour MK, Lowy DR: TGF alpha enhances locomotion of cultured human keratinocytes. J Invest Dermatol, 100: 628-632, 1993. [PubMed] [Google Scholar]
[15]	Grant MB, Khaw PT, Schultz GS, Adams JL, Shimizu RW: Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-β on corneal cell chemotaxis. Investig Ophthalmol Vis Sci, 33(12): 3292-301, 1992. [PubMed] [Google Scholar]
[16]	Bodnar RJ: Epidermal growth factor and epidermal growth factor receptor: the yin and yang in the treatment of cutaneous wounds and cancer. Adv Wound Care, 2(1): 24-9, 2013. [PMC free article] [PubMed] [Google Scholar]
[17]	Laidding SR, Josh F, Battung S, Bukhari A, et al.: Combination of platelet rich plasma and stromal vascular fraction on the level of vascular endothelial growth factor in rat subjects experiencing deep dermal burn injury. Ann Med Surg, 64: 102254, 2021, https://doi.org/10.1016/j.amsu.2021.102254
[18]	Eric J Yang, Aleksi J Hendricks, Kristen M Beck, Vivian Y Shi. Bioactive: A new era of bioactive ingredients in topical formulations for inflammatory dermatoses Affiliations expand PMID: 31583790 Dermatol Ther. 2019 Nov; 32(6): e13101. https://doi.org/10.1111/dth.13101 (Epub 2019 Oct 11)

Cite This Article

Plain Text BibTeX RIS

APA Style

Huyu, L., Dongdong, L., Chao, L. (2024). Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clinical Medicine Research, 13(2), 23-28. https://doi.org/10.11648/j.cmr.20241302.12

Copy | Download

ACS Style

Huyu, L.; Dongdong, L.; Chao, L. Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clin. Med. Res. 2024, 13(2), 23-28. doi: 10.11648/j.cmr.20241302.12

Copy | Download

AMA Style

Huyu L, Dongdong L, Chao L. Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clin Med Res. 2024;13(2):23-28. doi: 10.11648/j.cmr.20241302.12

Copy | Download

@article{10.11648/j.cmr.20241302.12,
  author = {Li Huyu and Liu Dongdong and Liu Chao},
  title = {Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema
},
  journal = {Clinical Medicine Research},
  volume = {13},
  number = {2},
  pages = {23-28},
  doi = {10.11648/j.cmr.20241302.12},
  url = {https://doi.org/10.11648/j.cmr.20241302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20241302.12},
  abstract = {Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema

AU  - Li Huyu
AU  - Liu Dongdong
AU  - Liu Chao
Y1  - 2024/05/30
PY  - 2024
N1  - https://doi.org/10.11648/j.cmr.20241302.12
DO  - 10.11648/j.cmr.20241302.12
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 23
EP  - 28
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20241302.12
AB  - Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.

VL  - 13
IS  - 2
ER  -

Copy | Download

Author Information

Li Huyu

Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia

Contact Email

http://orcid.org/0009-0002-2161-0484
Liu Dongdong

Dermatology Department, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Contact Email

http://orcid.org/0009-0009-0415-131X
Liu Chao

Faculty of Medicine, Universitas Prima Indonesia, Medan, Indonesia

Contact Email

http://orcid.org/0000-0001-6066-0340

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Huyu, L., Dongdong, L., Chao, L. (2024). Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clinical Medicine Research, 13(2), 23-28. https://doi.org/10.11648/j.cmr.20241302.12

Copy | Download

ACS Style

Huyu, L.; Dongdong, L.; Chao, L. Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clin. Med. Res. 2024, 13(2), 23-28. doi: 10.11648/j.cmr.20241302.12

Copy | Download

AMA Style

Huyu L, Dongdong L, Chao L. Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema. Clin Med Res. 2024;13(2):23-28. doi: 10.11648/j.cmr.20241302.12

Copy | Download

@article{10.11648/j.cmr.20241302.12,
  author = {Li Huyu and Liu Dongdong and Liu Chao},
  title = {Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema
},
  journal = {Clinical Medicine Research},
  volume = {13},
  number = {2},
  pages = {23-28},
  doi = {10.11648/j.cmr.20241302.12},
  url = {https://doi.org/10.11648/j.cmr.20241302.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20241302.12},
  abstract = {Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Efficacy of Combination Therapy with External Human Epidermal Growth Factor and Ebastin in 60 Cases of Eczema

AU  - Li Huyu
AU  - Liu Dongdong
AU  - Liu Chao
Y1  - 2024/05/30
PY  - 2024
N1  - https://doi.org/10.11648/j.cmr.20241302.12
DO  - 10.11648/j.cmr.20241302.12
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 23
EP  - 28
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20241302.12
AB  - Objective: The primary aim of this research endeavor was to meticulously evaluate the efficacy and safety profile of integrating external human epidermal growth factor (EGF) with ebastine in the therapeutic management of eczema, Methods: A comprehensive cohort comprising sixty patients clinically diagnosed with eczema and admitted to our esteemed medical facility during the period spanning from June 2020 to June 2022 was meticulously curated for this investigation. Employing a rigorous randomized allocation procedure, the recruited patients were stratified into two distinct groups: the control group and the study group. The control group, serving as the comparative benchmark, underwent treatment with conventional ebastine therapy, whereas the study group was subjected to a novel therapeutic regimen encompassing the combined administration of external human epidermal growth factor and ebastine. Throughout the study duration, each patient's response to treatment was diligently monitored and meticulously documented. Results: Upon comprehensive analysis of the treatment outcomes, it was unequivocally evident that the therapeutic regimen involving the concomitant administration of external human epidermal growth factor and ebastine yielded markedly superior outcomes in comparison to the conventional ebastine monotherapy. Specifically, the study group exhibited an impressively high effective rate of 96.7%, which starkly contrasted with the comparatively modest effective rate of 73.3% observed in the control group (P < 0.05). Moreover, the incidence of adverse reactions in the study group was notably lower, standing at 13.3%, as opposed to the substantially higher incidence rate of 46.7% documented in the control group (P < 0.05). These compelling findings underscore the profound therapeutic potential and favorable safety profile associated with the innovative combination therapy. Conclusions: In light of the compelling evidence gleaned from this meticulously conducted study, it can be unequivocally concluded that the integration of external human epidermal growth factor with ebastine holds immense promise as a novel therapeutic strategy for the effective management of eczema. These findings advocate for the wider adoption and integration of this innovative therapeutic approach into mainstream clinical practice, thereby signifying a pivotal advancement in the armamentarium against this debilitating dermatological ailment.

VL  - 13
IS  - 2
ER  -

Copy | Download